首页 正文

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment

{{output}}
Tissue-agnostic therapies, which target molecular alterations across cancer types, have been approved by the US Food and Drug Administration (FDA) since 2017. These approvals were based on clinical trials enrolling patients across diverse tumor types, regardle... ...